Latest for KCNT1-Related Epilepsy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
More about KCNT1-Related Epilepsy
Potassium channels act as brakes on electrical activity in neurons. The disease-causing changes in KCNT1 are gain-of-function variants, meaning the channel opens too readily and passes too much current. Counterintuitively, a channel that should quiet neurons produces severe epilepsy when overactive, most likely because the effect falls hardest on inhibitory interneurons whose job is to restrain the rest of the network.
Keep reading about KCNT1-Related Epilepsy
The severe end of the spectrum is epilepsy of infancy with migrating focal seizures (EIMFS), first linked to KCNT1 in 2012. Seizures usually begin within the first weeks to months of life. On EEG they migrate, starting in one cortical region and shifting to another and across hemispheres, which is the finding that gives the syndrome its name.
Autonomic features such as apnea, perioral cyanosis, and flushing are common and can be frightening for parents. Seizures typically escalate to become nearly continuous by six to nine months. Development arrests once seizures begin: many children never sit, walk, or speak. Mortality in early childhood is substantial.
The milder end is sleep-related hypermotor epilepsy (SHE), historically called autosomal dominant nocturnal frontal lobe epilepsy. Here, seizures come in clusters during sleep and involve sudden vigorous movements that can be mistaken for night terrors or other parasomnias. Seizure burden is lower, but cognitive and psychiatric difficulties are common and can be more disabling than the seizures themselves. Between these two poles sit other focal epilepsies and developmental and epileptic encephalopathies that do not fit either label cleanly, and reports have described features outside the nervous system as well.
Diagnosis is made by genetic testing, usually an epilepsy gene panel, exome sequencing, or genome sequencing. Because the specific variant carries implications for both prognosis and emerging targeted treatment, confirming the genetic diagnosis matters even when the clinical picture already looks like EIMFS.
What are the symptoms of KCNT1-Related Epilepsy?
These are common symptoms of KCNT1-Related Epilepsy, and how strong they are varies from person to person.
- Focal seizures beginning in the first six months of life, often within the first weeks
- Seizures that migrate from one brain region to another and from one side to the other, visible on EEG
- Seizures that become nearly continuous by six to nine months of age in the infantile form
- Autonomic signs during seizures including apnea, perioral blueness (cyanosis), and flushing
- Developmental plateau or regression once seizures begin, with loss or non-attainment of milestones such as sitting, walking, and speaking
- Clusters of brief hypermotor seizures during sleep in the later-onset form, sometimes mistaken for parasomnias or night terrors
- Poor head growth, low muscle tone, and feeding difficulties
- Seizures that do not respond to multiple antiseizure medications (pharmacoresistance)
- Cognitive and psychiatric difficulties in the later-onset form, sometimes out of proportion to seizure burden
Who gets KCNT1-Related Epilepsy?
KCNT1-related epilepsy is inherited in an autosomal dominant manner, but most affected children are the only person in their family with the condition. Their variant arose new (de novo) at conception rather than being passed down. Families with the later-onset sleep-related form more often show the variant across multiple generations. Both sexes are affected.
The age at onset largely sorts the two presentations. The infantile developmental and epileptic encephalopathy form begins in the first six months of life, with roughly 80% of cases starting in infancy. The sleep-related hypermotor form typically begins in later childhood, adolescence, or adulthood. Genotype tends to track with phenotype: variants in the first regulator of conductance of potassium (RCK1) domain are more often associated with the severe infantile form, while variants in the RCK2 domain are more often associated with the sleep-related form.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Which new KCNT1-Related Epilepsy medicines are in trials?
Investigational medicines Trial Friend tracks for KCNT1-Related Epilepsy, with trial results, safety findings and where each one stands.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for KCNT1-Related Epilepsy
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted KCNT1-Related Epilepsy resources
Reputable organizations and medical references for learning more about KCNT1-Related Epilepsy, including disease registries, foundation resources, and clinical guidelines.